Ironshore Inc. has promoted Steven Horton vice president, Financial Lines Manager, within Iron-Starr Excess Agency Ltd., based in Bermuda.
Horton joined Ironshore’s Pembroke Syndicate in London in 2008, where he served as a financial institutions underwriter. He joined Iron-Starr in Bermuda in 2010, responsible for underwriting and building the financial lines business throughout the Ironshore platform. Prior to Ironshore, Horton worked for Chartis Excess Limited in London as a financial lines underwriter.
Iron-Starr Excess Agency Ltd., a joint venture between Ironshore Inc. and C.V. Starr & Co. Inc. that was formed in 2009, is a specialty lines insurance managing general underwriting agency, domiciled in Bermuda.
Sunday, August 11, 2013
Saturday, August 10, 2013
BMD Correlates with Number of HIV Regimens (CME/CE)
BMD Correlates with Number of HIV Regimens (CME/CE)
The number of HIV treatment regimens a patient undergoes appears to correlate with loss of bone mineral density (BMD), researchers reported here at the International Aids Society Conference on HIV Pathogenesis, Treatment, and Prevention.
The number of HIV treatment regimens a patient undergoes appears to correlate with loss of bone mineral density (BMD), researchers reported here at the International Aids Society Conference on HIV Pathogenesis, Treatment, and Prevention.
Tuesday, August 6, 2013
Blood Test May Flag Impending COPD Flares (CME/CE)
Blood Test May Flag Impending COPD Flares (CME/CE)
Easily measured biomarkers of inflammation could give advance warning of chronic obstructive pulmonary disease (COPD) exacerbations, researchers said.
When COPD patients in a prospective Danish study had high levels of C-reactive protein (CRP), serum fibrinogen, and leukocyte count, their risk of experiencing a disease flare during the following year was increased by a factor of 2.5 (95% CI 1.8-3.4) compared with patients who did not have high values for any of these measures, according to Børge Nordestgaard, DMSc, of Copenhagen University Hospital in Denmark, and colleagues.
Easily measured biomarkers of inflammation could give advance warning of chronic obstructive pulmonary disease (COPD) exacerbations, researchers said.
When COPD patients in a prospective Danish study had high levels of C-reactive protein (CRP), serum fibrinogen, and leukocyte count, their risk of experiencing a disease flare during the following year was increased by a factor of 2.5 (95% CI 1.8-3.4) compared with patients who did not have high values for any of these measures, according to Børge Nordestgaard, DMSc, of Copenhagen University Hospital in Denmark, and colleagues.
Monday, August 5, 2013
Switch to Quad Pill Maintained HIV Suppression (CME/CE)
Switch to Quad Pill Maintained HIV Suppression (CME/CE)
HIV patients can be successfully switched from a twice-daily integrase inhibitor regimen to a once-daily, single-tablet regimen without loss of viral suppression, researchers reported here.
At 48 weeks, all 46 patients who switched from a raltegravir-based (Isentress) regimen to the four-drug, elvitegravir-cobicistat-tenofovir-emtricitabine (Stribild) pill were able to maintain undetectable viral load using the 50 copies/ml assay, said Gordon Crofoot, MD, a Houston-based HIV researcher in private practice.
HIV patients can be successfully switched from a twice-daily integrase inhibitor regimen to a once-daily, single-tablet regimen without loss of viral suppression, researchers reported here.
At 48 weeks, all 46 patients who switched from a raltegravir-based (Isentress) regimen to the four-drug, elvitegravir-cobicistat-tenofovir-emtricitabine (Stribild) pill were able to maintain undetectable viral load using the 50 copies/ml assay, said Gordon Crofoot, MD, a Houston-based HIV researcher in private practice.
Sunday, August 4, 2013
Quad Pill for HIV Appears Safe in Renal Disease (CME/CE)
Quad Pill for HIV Appears Safe in Renal Disease (CME/CE)
HIV patients with mild to moderate renal impairment appear to tolerate treatment with a combination tablet that contains drugs known to impact kidney function, a phase III, open-label, two-cohort study found.
The treatment group receiving the four-drug combination of elvitegravir, cobicistat, tenofovir DF, and emtricitabine, branded as Stribild, saw a small impact on estimated creatinine clearance (eCCr), but the change rapidly plateaued and may not be clinically meaningful, Frank Post, MD, a reader in HIV at Kings College Hospital in London, told MedPage Today
HIV patients with mild to moderate renal impairment appear to tolerate treatment with a combination tablet that contains drugs known to impact kidney function, a phase III, open-label, two-cohort study found.
The treatment group receiving the four-drug combination of elvitegravir, cobicistat, tenofovir DF, and emtricitabine, branded as Stribild, saw a small impact on estimated creatinine clearance (eCCr), but the change rapidly plateaued and may not be clinically meaningful, Frank Post, MD, a reader in HIV at Kings College Hospital in London, told MedPage Today
Saturday, August 3, 2013
Single HIV Pill Not Always Best (CME/CE)
Single HIV Pill Not Always Best (CME/CE)
HIV patients taking single pills containing three drugs are thought to be less likely to stop taking their medications than those on more complicated regimens, but that may not be completely accurate, researchers said here.
In a retrospective, observational study, people taking the most widely used single pill were just as likely to switch therapies as were those on multipill regimens, according to Benoit Trottier, MD, of Clinique Medicale L'Actuel in Montreal, and colleagues at the AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention.
HIV patients taking single pills containing three drugs are thought to be less likely to stop taking their medications than those on more complicated regimens, but that may not be completely accurate, researchers said here.
In a retrospective, observational study, people taking the most widely used single pill were just as likely to switch therapies as were those on multipill regimens, according to Benoit Trottier, MD, of Clinique Medicale L'Actuel in Montreal, and colleagues at the AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention.
Friday, August 2, 2013
Quad Pill Works Over 2 Years (CME/CE)
Quad Pill Works Over 2 Years (CME/CE)
In pooled results from two randomized clinical trials, treatment with the four-drug, once-daily single tablet (Stribild) continued to show efficacy comparable with other anti-HIV regimens out to 96 weeks, researchers said here.
After 96 weeks, 84% of patients on the 'quad' achieved undetectable suppression of HIV using the 50 copies/mm3 assay compared with viral suppression in 82% of patients on the combination of efavirenz-emtricitabine-tenofovir (Atripla), said David Cooper, MD, professor of medicine at the Kirby Institute, University of New South Wales, Sydney.
In pooled results from two randomized clinical trials, treatment with the four-drug, once-daily single tablet (Stribild) continued to show efficacy comparable with other anti-HIV regimens out to 96 weeks, researchers said here.
After 96 weeks, 84% of patients on the 'quad' achieved undetectable suppression of HIV using the 50 copies/mm3 assay compared with viral suppression in 82% of patients on the combination of efavirenz-emtricitabine-tenofovir (Atripla), said David Cooper, MD, professor of medicine at the Kirby Institute, University of New South Wales, Sydney.
Subscribe to:
Posts (Atom)